Oscar's New $500M-$700M Profit Target Puts Its MLR Bet on Trial

Oscar's improved first half raises the bar for the rest of 2026

This update is about more than better numbers. It is about how quickly the market will reprice Oscar if investors decide the turnaround is durable. Management pointed to record profitability in the first half of 2026, including a 75.0% first-half MLR and a 14.7% SG&A ratio. If investors view that improvement as sustainable, the stock becomes a bet on whether the operating turn can hold through the second half.

Why the baseline matters

The stakes look higher because the prior year was so weak. In 2025, Oscar swung to a $396.4 million loss from earnings from operations and a $443.2 million net loss. That backdrop makes any recovery stand out, but it also raises the risk of confirmation bias. One strong half is meaningful evidence, not final proof.

The real question is durability

In 2025, revenue rose to $11.7 billion while the medical loss ratio worsened to 87.4%. That was growth under margin pressure, not clean profit compounding. The first-half MLR of 75.0%, compared with 83.0% a year earlier, gives investors real evidence of improvement. The key question now is whether that improvement can survive another morbidity or utilization shock.

MLR drives the profit target more than the headline number does

The formula behind the guidance

The headline is the profit target. The mechanism is the formula. Earnings from operations is simply what remains after claims and operating expenses are deducted from revenue. That is why Oscar's full-year framework matters most in its components: management now expects $18.7-$19.0 billion of revenue, 82.4%-83.4% MLR, 15.8%-16.3% SG&A, and $250-$450 million of earnings from operations.

Once the guidance is viewed this way, the debate changes. The issue is not only whether $450 million sounds compelling. It is whether the assumed claim ratio and expense ratio are credible enough to make that range achievable.

First-half results were stronger than the full-year guide

In the first half of 2026, Oscar generated about $9.5 billion of revenue, posted a 75.0% MLR, and ran SG&A at 14.7%. Those figures are better than what the full-year guide implies the company needs to hold for the year. Practically, that means if second-half performance trends back toward the guided range, earnings could land nearer the low end rather than the midpoint.

It also helps explain the title's framing: if revenue and cost trends land toward the higher end of the guided MLR band, the profit outcome can still be substantially below a $500 million-$700 million narrative. The current official range stops at $450 million, so any case beyond that depends on better-than-guided performance.

Why a Q1 beat alone can be misleading

The Q1 result matters, but mainly as a behavioral cue. Oscar reported $2.07 EPS versus $1.21 expected, a 71.5% positive surprise. That kind of move can tempt investors to treat one strong quarter as proof of a new regime. More carefully, it shows the model can work when medical costs come in better than expected and cost control holds.

What would support the bull case

The constructive case has a real operating mechanism, not just hope. Management has pointed to consumer products, disciplined pricing, and a scalable technology platform. The first-half results show the model can improve quickly when execution is strong.

What keeps the bear case alive

The skeptical case is not baseless. In 2025, revenue still grew, but MLR worsened, earnings from operations fell to a $396.4 million loss, and adjusted EBITDA dropped to a $279.8 million loss. That history suggests MLR improvement can be fragile if morbidity or utilization rise faster than pricing and care management can absorb them.

What investors should watch next

The clearest signals are straightforward: - whether MLR stays close to the guided 82.4%-83.4% range - whether SG&A stays near or below 15.8%-16.3% - whether the first-half operating turn repeats across multiple quarters

If those assumptions hold, the guidance range becomes easier to trust. If not, the profit outlook will look more aspirational than certain.

How the story likely gets traded from here

After a guidance raise tied to record profitability in the first half of 2026, the market can no longer treat the turnaround as purely theoretical. Management also lifted the full-year framework to $250-$450 million of earnings from operations on expectations for $18.7-$19.0 billion of revenue. That means part of the improvement is already embedded in the setup.

What would confirm the rebound

The cleanest confirmation is continuity, not another headline beat. Investors should look for the same mix of operating performance and cost control to show up again over the next few quarters.

What would expose an overreaction

The faster route back to skepticism is familiar: the business looks healthy for a quarter or two, then shows that the improvement was only temporary.

After today, the practical read is simple: bulls need repetition, and bears need one weak quarter.